Market Overview

Westlake Village BioPartners Unveils $320 Million Inaugural Fund Focused on Life Science Investing

Share:

Launched by longtime life sciences investor Dr. Beth Seidenberg and
to be co-led by R&D veteran Dr. Sean Harper

Westlake
Village BioPartners
, a new venture firm exclusively focused on
investing in life sciences, announced the launch of the firm's first
fund with $320 million of committed capital. The founding team will
include industry veterans and managing directors, Beth Seidenberg, M.D.
– general partner at Kleiner Perkins and former chief medical officer
and head of global development at Amgen – and Sean Harper, M.D.,
executive vice president and head of R&D at Amgen who will move to the
firm in January 2019. Dr. Seidenberg and Dr. Harper will lead Westlake's
investing activities. Scott Ryles, chief operating officer at Kleiner
Perkins, will be Westlake's chief operating officer.

The Westlake approach is distinctive and based on Dr. Seidenberg's
successful track record in venture investing. The firm will invest in
early-stage opportunities and incubating companies, matching the best
entrepreneurial talent with promising, carefully-selected technologies
from academia, companies, or de novo assets with breakthrough potential.
Westlake will also make select investments in later-stage companies,
creating a diversified portfolio.

"I am thrilled to launch a new fund dedicated to investing in life
sciences and appreciate the support of our limited partners," commented
Dr. Seidenberg. "This was the ideal time – both in my role at Kleiner
Perkins and given the explosive growth of breakthroughs in science and
medicine – to pursue my passion for life sciences and launch a fund with
such an exceptional team with whom I've worked closely in prior roles.
Sean and I have known each other for more than 20 years and bring unique
insights and expertise from our time in the drug discovery and
development industry, providing the perfect shared history upon which to
build Westlake. We look forward to sharing more information about the
fund and our investment priorities in the coming months."

About the Westlake Village BioPartners Founding Team

Together, the Westlake founders have years of experience leading large
organizations and collaborating with teams to advance assets rapidly and
efficiently. The founders' networks span pharmaceutical, biotech and
financial industries, providing insights regarding business development
and M&A. Westlake is the first large venture fund of its kind based in
the greater Los Angeles area, an emerging cluster of medical innovation
and excellence in academic research with a deep talent pool.

Dr. Seidenberg has incubated-invested 13 biotech ventures since January
2006, including ARMO, Arresto, Atara, Cell Design Labs, iPierian,
Epizyme, Flexus, TESARO and True North. She has significant senior level
industry experience – with leadership roles at Amgen, Bristol-Myers
Squibb and Merck Research Laboratories – and a demonstrated ability to
identify and accelerate medically meaningful molecules through
development. Dr. Seidenberg graduated from the University of Miami
School of Medicine and thereafter completed her medical residency at
Johns Hopkins and the George Washington University and Fellowship at the
National Institutes of Health.

Dr. Harper brings more than 20 years of drug development experience at
top pharmaceutical and large cap biotech companies, as well as M&A
experience, and experience with Amgen's venture fund. Under his
leadership tenure at Amgen and Merck, 14 new products were successfully
developed, including Prolia, Repatha, Blincyto and Aimovig. In addition,
he created an industry-leading position for Amgen in human population
genetics target discovery and validation capability. Dr. Harper attended
medical school at the University of California at San Francisco,
completed internal medicine and gastroenterology training at the
Massachusetts General Hospital, and was a postdoctoral fellow at the
Massachusetts Institute of Technology.

Scott Ryles brings extensive operational and financial expertise
including CEO roles in asset management, investment banking and
insurance. He has been the chief operating officer of Kleiner Perkins
since 2014, and previously was the CEO of two Kleiner Perkins portfolio
companies. Mr. Ryles has held numerous board seats at private and public
companies, including Gymboree and KKR Financial, and currently sits on
the boards of ClearStory Data and Cloud Physics.

About Westlake Village BioPartners

Westlake Village BioPartners is a Los Angeles area-based venture capital
firm focused on incubating and building life sciences companies with
entrepreneurs that have the potential to bring transformative therapies
and technologies to patients. The Westlake model is built on the
founding team's unique experience in successfully identifying and
developing breakthrough therapies and building organizations. For more
information, please visit http://westlakebio.com/.

View Comments and Join the Discussion!